Moderate Evidence
Research Overview
Alixorexton Research for Excessive Daytime Sleepiness
An evidence-based overview of research examining Alixorexton in the context of excessive daytime sleepiness. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 data showed dose-dependent improvements in objective wakefulness measures. Patients demonstrated significant increases in MWT sleep latency and improved subjective sleepiness scores on the Epworth Sleepiness Scale compared to placebo.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Excessive Daytime Sleepiness
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Alixorexton may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.